1 not yet recruiting, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow Extrapulmonary Neuroendocrine Carcinoma: new trials by email Literature Review of Extrapulmonary Neuroendocrine Carcinoma trials Research Report on Extrapulmonary Neuroendocrine Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC Benmelstobart+ Anlotinib+ Platinum + Etoposide - Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 48 | 2026-05-01 | 2026-04-03 |
| Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer Tarlatamab, Sacituzumab Govitecan - Extensive-Stage Small Cell Lung Cancer, Extrapulmonary Neuroendocrine Carcinoma | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2026-04-25 | 2026-04-28 |
Carcinoma, Small Cell (1) · Small Cell Lung Carcinoma (1)
Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Etoposide (1) · sacituzumab govitecan (1)
National Cancer Institute (NCI) (1) · Tianjin Medical University Cancer Institute and Hospital (1)
China (1) · United States (1)